BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

Market Cap	20.92B +41.9%
Revenue (ttm)	1.22B -4.6%
Net Income	54.51M -70.4%
EPS	0.13 -71.1%
Shares Out	422.54M
PE Ratio	383.83
Forward PE	n/a
Dividend	0.02 (0.03%)
Ex-Dividend Date	Jun 23, 2025

Volume	18,027,800
Average Volume	13,617,365
Open	46.00
Previous Close	46.49
Day's Range	45.75 - 50.58
52-Week Range	32.01 - 122.59
Beta	0.17
RSI	58.66
Earnings Date	Mar 20, 2026

About SHA:688166

BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, inc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 1,162
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688166

Financial Performance

In 2025, SHA:688166's revenue was 1.22 billion, a decrease of -4.59% compared to the previous year's 1.28 billion. Earnings were 56.06 million, a decrease of -70.37%.